Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.

go big — Merck & Co. is planning a big Phase III program for its oral PCSK9 inhibitor • Source: Shutterstock

Merck & Co., Inc. is moving aggressively to bring the first oral PCSK9 inhibitor to market and outlined an ambitious late-stage clinical trial program for MK-0616 during an investor event at the American College of Cardiology annual meeting on 6 March.

Merck is looking to develop MK-0616 for a broad audience, and with oral administration, the company believes the drug could...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

17 Jun 2025

• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

09 Jun 2025

• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

21 May 2025

• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

20 May 2025

• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.